Furthermore, mutations or deletions in the CDKN2A/B gene are associated with various tumors, including breast cancer, melanoma, ovarian cancer, and lung adenocarcinoma (ShahidSales et al. 2018; Chan et al. 2017; Reinhardt et al. 2018; Cocco et al. 2017; Jiang et al. 2016; Mullighan and Downing 2009). Here, CDKN2A is linked to ovarian cancer.